BSIM Therapeutics is awarded a second US Patent

03 November, 2021

Large 1565721326745

For the second time around, BSIM Therapeutics has been awarded a United States Patent (Patent no. 11,117,877) for yet another novel technology directed to the treatment of transthyretin amyloidosis (ATTR). The protected chemical series of transthyretin (TTR) stabilizers represents a landmark advance in the pursuit of molecular “chaperones” displaying resilience towards mutations that affect TTR stability and binding affinity, while also encompassing a wide range of versatile, drug-like and safe compounds aimed at the organ-targeted treatment of ATTR.

With this new addition, BSIM takes a step forward in the consolidation of a strong Intellectual Property portfolio and in its efforts to answer to multiple unmet medical needs of ATTR patients.

More news soon. Stay tuned!

By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more